Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA)
announced today that the Company has been issued U.S. Patent No.
6,878,550 for its diagnostic breath test kit, Diatest(R). The patent
entitled "13C Glucose Breath Test for the Diagnosis of Diabetic
Indications and Monitoring Glycemic Control" is the fifth U.S.
Patent issued for this technology.
The Diatest(R), a 13C glucose breath test, provides both
physicians and their patients with an effective means to investigate
insulin resistance. Based on the results of the test physicians can
implement treatment to prevent or delay the medical conditions
associated with insulin resistance, such as type 2 diabetes. The
Company is planning to conduct a North American trial for the
Diatest(R), to further validate the kit and provide the necessary
clinical data to obtain regulatory approval to market the test in the
United States and other countries. The Diatest(R) FDA trial is
expected to commence by the third quarter of 2005.
The Company currently has regulatory approval and the required
license to sell the Diatest(R) in Canada. The clinical data obtained
from the North American trial will assist the Company in marketing
the Diatest(R) in Canada and international markets.
"We are pleased to receive this latest patent on this exciting new
technology. We are currently in development of this test to provide
clinicians and patients with a tool capable of diagnosing
pre-diabetic disease in a simple, non-invasive yet cost-effective
manner," commented Mr. Joseph Koziak, Isotechnika's Executive Vice
President. "The Diatest(R) has the potential to become the gold
standard in insulin resistance testing."
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world-class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 is an immunosuppressant
currently in a Canadian Phase III human clinical trial for the
treatment of moderate to severe psoriasis. In addition, ISA247 has
successfully completed a Phase IIa trial for kidney transplantation.
The Company also has two additional immunosuppressive compounds in
its drug pipeline, TAFA93 and TKB662 which are in Phase I and
In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(R) and Diatest(R)
breath kits. The Helikit(R) a 13C urea breath test is used for the
detection of H. pylori, a bacterium that infects a large portion of
the population. The Diatest(R) a 13C glucose breath test is used to
measure insulin resistance.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
This press release may contain forward-looking statements.
Forward- looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward- looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.
ots Originaltext: Isotechnika, Inc
Im Internet recherchierbar: http://www.presseportal.ch
Joseph Koziak, Executive Vice President, Isotechnika Inc., Phone:
+1-(480)-505-0540, Fax: +1-(480)-484-4105, Email:
firstname.lastname@example.org; Stephanie Gillis-Paulgaard, Senior Manager,
Corporate Communications, Isotechnika Inc., Phone: +1-(780)-487-1600
Ext. 243, Fax: +1-(780)-484-4105,
E-mail:email@example.com; Archived images on this
organization are searchable through CNW Photo Archive website at
http://photos.newswire.ca. Images are free to accredited members of
the media; To request a free copy of this organization's annual
report, please go to http://www.newswire.ca and click on reports@cnw